Neurodevelopmental disability at 18 to 24 months among survivors · respiratory failure in infants born at or near term
Inhaled NO at moderate showed no clear difference in neurodevelopmental disability at 18 to 24 months among survivors compared with severe criteria (moderate certainty).
1 finding from 1 review
Death or use of ECMO; infants with diaphragmatic hernia · respiratory failure in infants born at or near term
Inhaled NO showed no clear difference in death or use of ECMO; infants with diaphragmatic hernia compared with control (moderate certainty).
1 finding from 1 review
Death at hospital discharge · respiratory failure in infants born at or near term
Inhaled NO showed no clear difference in death before hospital discharge; studies that did not allow back‐up… compared with control (high certainty).
1 finding from 1 review
Death before hospital discharge; infants with diaphragmatic hernia · respiratory failure in infants born at or near term
Inhaled NO showed no clear difference in death before hospital discharge; infants with diaphragmatic hernia compared with control (moderate certainty).
1 finding from 1 review
Use of ECMO before hospital discharge · respiratory failure in infants born at or near term
Inhaled NO leads to lower use of ECMO before hospital discharge; studies that did not allow… compared with control (high certainty).
1 finding from 1 review
Use of ECMO before hospital discharge; infants with diaphragmatic hernia · respiratory failure in infants born at or near term
Inhaled NO showed no clear difference in use of ECMO before hospital discharge; infants with diaphragmatic… compared with control (moderate certainty).
1 finding from 1 review
Neurodevelopmental disability at 18 to 24 months among survivors · respiratory failure in infants born at or near term
Inhaled NO showed no clear difference in neurodevelopmental disability at 18 to 24 months among survivors compared with control (low certainty).
1 finding from 1 review
Death or requirement for ECMO · respiratory failure in infants born at or near term
Inhaled NO at moderate showed no clear difference in death or requirement for ECMO compared with severe criteria (low certainty).
1 finding from 1 review
Mortality before hospital discharge · respiratory failure in infants born at or near term
Inhaled NO at moderate showed no clear difference in death before hospital discharge compared with severe criteria (moderate certainty).
1 finding from 1 review
Mortality before hospital discharge · respiratory failure in preterm infants
Inhaled NO showed no clear difference in death before discharge ‐ Studies with entry before 3 days based on… compared with control (high certainty).
3 findings from 1 review
RR 1.02 [0.89, 1.18]
10 studies · 1066 participants
High
RR 1.18 [0.81, 1.71]
3 studies · 1075 participants
High
RR 0.9 [0.74, 1.1]
4 studies · 1924 participants
Moderate
Neurodevelopmental disability · respiratory failure in preterm infants
Inhaled NO showed no clear difference in neurodevelopmental disability ‐ Studies with entry after 3 days… compared with control (moderate certainty).
3 findings from 1 review
RR 0.9 [0.74, 1.09]
2 studies · 498 participants
Moderate
RR 0.91 [0.74, 1.13]
3 studies · 1223 participants
High
RR 1.05 [0.78, 1.4]
2 studies · 208 participants
Moderate
Death or bronchopulmonary dysplasia · respiratory failure in preterm infants
Inhaled NO showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks ‐ Studies with entry… compared with control (high certainty).
2 findings from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · respiratory failure in preterm infants
Inhaled NO showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks ‐ Studies with entry… compared with control (high certainty).
1 finding from 1 review
Overall mortality · people with cancer who have febrile neutropenia
Mortality with anti‐gram‐positive antibiotics showed no clear difference in overall mortality compared with placebo (moderate certainty).
1 finding from 1 review
Overall failure (disregarding modifications) · people with cancer who have febrile neutropenia
Treatment failure with anti‐gram‐positive antibiotics showed no clear difference in overall failure (disregarding modifications) compared with placebo (low certainty).
1 finding from 1 review
Failure, modifications included · people with cancer who have febrile neutropenia
It is very uncertain whether treatment failure with anti‐gram‐positive antibiotics changes failure, modifications included compared with placebo (very low certainty).
1 finding from 1 review
Any adverse events · people with cancer who have febrile neutropenia
It is very uncertain whether adverse events with anti‐gram‐positive antibiotics changes any adverse events compared with placebo (very low certainty).
1 finding from 1 review
Intervention not reported
Survival at 1 year Estimated survival at 1 year based on trials of 6 and 9 months' duration · people with ALS/MND
1 finding from 1 review
Intervention not reported
Rate of decline in MVIC Expressed as arm megascore1 · people with ALS/MND
1 finding from 1 review
Intervention not reported
Rate of decline of % predicted FVC · people with ALS/MND
1 finding from 1 review